Preferred Label : Treatment Benefit;

NCIt definition : The direct or indirect impact of treatment as measured by outcome assessments of a patient's feelings, level of functioning, or survival.;

Alternative definition : CDISC-GLOSS: The impact of treatment as measured by survival or a COA of how patients feel or function. Direct evidence of treatment benefit is derived from clinical trial effectiveness endpoints that measure survival or a meaningful aspect of how a patient feels or functions in daily life. NOTE: Treatment benefit can be demonstrated by an advantage in either effectiveness or safety, or both. [After FDA Clinical Outcome Assessment (COA) Glossary];

NCI Metathesaurus CUI : CL540667;

Details


Main resources

You can consult :


https://www.cochrane.org/fr/CD014687/NEUROMUSC_quels-sont-les-benefices-et-les-risques-des-traitements-non-chirurgicaux-et-chirurgicaux-du-nevrome
2024
United Kingdom
review of literature
french abstract
Non-Surgical
Usually Need Help from Another Person for Walking
Hard to Walk More Than One Block
Walking
Morton Neuroma
Morton Neuroma
Symptoms Interfered with Walking
pain, nos
walking
gait, nos
risk assessment
Forward
Raw
morton's metatarsalgia
Treatment Benefit
risks and benefits
What Month is it
ball of foot
Foot Pain
pain

---
https://www.cochrane.org/fr/CD013414/RENAL_quels-sont-les-benefices-et-les-risques-de-lutilisation-de-la-metformine-dans-le-traitement-de-la
2024
United Kingdom
review of literature
french abstract
Metformin
renal insufficiency, chronic
kidney diseases
chronic disease
chronic disease, nos
Use
Chronic Kidney Disease, CTCAE
risk assessment
metformin
risks and benefits
Treatment Benefit
What Month is it
Chronic Renal Failure
kidney disease, nos

---
https://www.cochrane.org/fr/CD013271/NEONATAL_quels-sont-les-benefices-et-les-risques-du-traitement-par-corticosteroides-des-prematures-presentant
2024
United Kingdom
review of literature
french abstract
adrenal cortical hormone, nos
Premature Infant
Bronchopulmonary Dysplasia
risk assessment
immature
What Month is it
Corticosteroid
adrenal cortex hormones
Too Early
Preterm Birth
bronchopulmonary dysplasia
infant, premature
corticosteroid therapy
risk
Treatment Benefit
risks and benefits
bronchopulmonary dysplasia of newborn

---
https://www.cochrane.org/fr/CD014544/CF_quels-sont-les-benefices-et-les-risques-des-nouveaux-traitements-par-facteurs-non-coagulants-pour-la
2024
United Kingdom
review of literature
french abstract
risk factors
blood coagulation factors
hemophilia B
bloodletting
coagulants
Treatment Benefit
Feeding
Breeding
Risk Factor
Coagulation Factor
hemophilia b, nos
persons
risks and benefits
risk factor
F9 wt Allele
Feeding Ability
Prevention Study
Hemophilia B
What Month is it
disease
Raw
coagulation factor, nos
Hemorrhage
Preventive Intervention
risk assessment
bleeding precautions
hemorrhage
People
New Lesion Identification
Newar Language
preventive treatment, nos

---
Nous contacter.
31/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.